Exclusive Summary

• Oseltamivir Phosphate is a standard treatment for influenza, listed in the WHO Essential Medicines List, ensuring stable demand and significant market potential.
• With hundreds of millions affected by influenza annually, especially during epidemic seasons and in high-risk populations, there's a continuous and seasonally explosive demand for oseltamivir.
• As a mature generic drug, its significant cost advantage and multiple dosage forms facilitate rapid market penetration, particularly in emerging markets and public health procurement.
• Leveraging Chinese pharmaceutical companies' GMP standards and international registration experience, the product possesses strong competitiveness in quality and compliance for overseas market access.
• Despite intense competition, sustained efficacy, clear clinical status, and cost-effectiveness collectively drive the continued penetration of oseltamivir in the global market.